Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

First half gains wiped out
Wed, 4 Mar 03:30 pm

BSE-Sensex and NSE-Nifty eroded as much as 1.2% of the gains and is now trading in the red. Both the indices have fallen 0.7% each. BSE Sensex has fallen over 200 points, down 0.72%, while NSE Nifty is in red by 0.9% or 78 points. Selling pressure is prominent on BSE Mid Cap and BSE Small Cap indices. The midcap and smallcap companies are trading in the red with 1% losses each. Indian rupee is trading with a gain of 0.09, breaching the Rs 62 level. Both the precious metals, gold and silver, are trading in the red. Gold has fallen marginally by Rs 23 and is trading at Rs 26,450 per 10 grams; silver price has fallen by 0.20% to Rs 36,325 per kilogram. Crude oil price has jumped about 1% and is trading at Rs 3,168 per barrel.

European markets extended the sell-off, which started yesterday. DAX and FTSE have fallen about 0.61% and 0.24%, respectively. Yesterday, the respective indices fell about 1% each. This is the consequent effect of below than expected services PMI numbers. Service PMI across all major European economies came in below expectations.

The second half of the trading session witnessed profit booking. Selling pressure was witnessed in the banking sector and the Information technology sector. However, pharmaceutical sector witnessed robust gains today. Lupin and Glenmark Pharma witnessed gains of about 0.5%. However, Sun Pharma Advanced Research Company emerged as a front runner in gains. Stock of the company gained around 5% as USFDA approved the company's application for ELEPSIA XRTM. This is a medicine which is used on patients with age of 12 years or older suffering from epilepsy.

Further, the second phase of coal auction is set to start today. Metals and mining witnessed maximum profit booking in the second half of the trading session. Sesa Sterlite was the biggest loser among the Nifty 50 pack with a loss of about 4%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "First half gains wiped out". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.